huntingtons disease epidemiology forecast

DelveInsight's "Huntington’s disease - Epidemiology Forecast-2034" report delivers an in-depth understanding of the Huntington’s disease, historical and forecasted epidemiology as well as the Huntington’s disease trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Huntington’s disease (HD) Understanding

The DelveInsight’s Huntington’s disease market report gives a thorough understanding of Huntington’s disease. Huntington’s disease (HD) is a rare, incurable, genetic, progressive neurodegenerative disorder that causes brain cells, termed as neurons, to die in several areas of the brain, together with those that help control voluntary (intentional) movement. It is passed on (inherited) from a person’s parents and known to get worse over time, disturbing the patient’s physical movements, emotions, and cognitive abilities. Huntington’s disease is named after George Huntington, the physician who described it as hereditary chorea in 1872.

Huntington’s disease is caused by an error in the DNA commands that build our bodies and keep them running. DNA is made up of thousands of genes, and people with Huntington’s disease have a small fault in one gene, chromosome 4 – one of the 23 human chromosomes that carry a person’s entire genetic code. This defect is “dominant,” meaning that any person who inherits it from a parent with Huntington’s will develop the disease in the long run. The faulty gene codes the blueprint for a protein called huntingtin. This protein’s normal function is not yet known; however, it is called “huntingtin” because scientists acknowledged its defective form as the cause of Huntington’s disease. Over time, this defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression, and other mood changes. Huntington’s disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s.

The only cause behind the occurrence of Huntington’s disease is a faulty gene that results in parts of the brain gradually becoming impaired over time. It is inherited as an autosomal dominant trait.

A person is generally only at risk of developing it if one of the parents has or had it. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed “dominating” the other normal gene and resulting in the appearance of the disease. Both men and women can get it since the risk of transmitting the disorder from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.

The progression of Huntington’s disease can be described in five stages/phases. For diagnosis specialized x-ray studies such as computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or electroencephalography (EEG) may help confirm the diagnosis of Huntington’s disease. During CT scanning, a computer and x-rays are used to create a file showing cross-sectional images of the brain.

Huntington’s disease (HD) Epidemiology

The epidemiology section provides insights about the historical and current Huntington’s disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted Huntington’s disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.

In the year 2021, the total prevalent cases of Huntington’s disease were 80,170 in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted Huntington’s disease epidemiology [segmented as Total Prevalent cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease, Total Chorea associated cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease by age group, Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage and Total Treated cases of Huntington’s disease] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Huntington’s disease Epidemiology

The epidemiology segment also provides the Huntington’s disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with the current Huntington’s disease patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Huntington’s disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

• The report covers the descriptive overview of Huntington’s disease, explaining their causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Huntington’s disease.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The disease epidemiology covered in the report provides historical as well as forecasted Huntington’s disease epidemiology[segmented as Total Prevalent cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease, Total Chorea associated cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease by age group, Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage and Total Treated cases of Huntington’s disease] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Huntington’s disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Huntington’s disease.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Huntington’s disease (HD) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Huntington’s disease Epidemiology Segmentation

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Huntington’s disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Huntington’s disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Huntington’s disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Huntington’s disease?
• Out of all 7MM countries, which country would have the highest incident population of Huntington’s disease during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Huntington’s disease Disease market
• To understand the future market competition in the Huntington’s disease Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Huntington’s disease Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Huntington’s disease Disease market
• To understand the future market competition in the Huntington’s disease Disease market